Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amylyx Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.